



Case Study

POTALA KATUROHINYADI KWATHA IN KAPHAJA YAKRIT DALLUDARA (NON-ALCOHOLIC FATTY LIVER DISEASE): A CASE STUDY

Ashok Kumar Panda^{1*}, Jayram Hazra²

^{*1}Research Officer, ²Former Director, Central Ayurveda Research Institute for Hepato Biliary Disorders, Bharatpur, Bhubaneswar, India.

ABSTRACT

Non- alcoholic fatty liver disease (NAFLD) is also otherwise termed as Hepatic steatosis and *Kaphaja yakrit dalludara* in Ayurveda. 34 years male patient, highly educated from a high socio-economic group of Non vegetarian diet habit came to hospital with complain of anorexia, indigestion and distention for three months. The clinical findings revealed that he is slightly obese, hyperglycaemia and dyslipidimia along elevated liver enzymes with fatty liver in USG and Fibro scan. The case was treated with *Patolakaturohinyadi Kwatham* (PKK) in the dose was 30ml *Kasaya* with equal quantity of luke warm water twice daily in empty stomach preferable morning and evening for six months. This study proved that PKK can significantly reduced blood sugar, serum Lipids and liver enzymes within three months along with reduction weight and BMI, but change in liver architecture required six months in this therapy. The BARD score and NAFLD score changed to normal after six months of therapy. The patient was kept in observation for further one year without medication and advised to practice *Yoga*, exercise and low carbohydrate and fat diet to study the recurrence of disease. The liver architecture as well as biochemical profile of liver is maintained after one year also. PKK may correct the metabolic dysfunction by increase *Agni*, digest *Ama* which helped in the correction of hyperglycaemia and dyslipidaemia. PKK is safe in for six months of use in recommended dose (30ml BID) as there was no adverse sign and symptom observed and no change in biochemical and Haematological profile of Patients. PKK is safe and effective in this case of *Kaphaja Yakrit dalludara* (NAFLD). It can study further in large population to generated evidence for its efficacy and efficacy in larger group.

KEYWORDS: *Kaphaja yakrit dalludara*, Non-alcoholic fatty liver disease (NAFLD), *Patolakaturohinyadi Kwatham* (PKK).

INTRODUCTION

Yakrit dalludara is broad term in Ayurveda where the increase in size of Liver (*Yakrit vridhi*). When there is an increase of *Kapha dosa* leads to increase in size of Liver, then *Kaphaja Yakrit dalludara* takes place. Then it increase the *Meda* inside the *Yakrit* leads to *Medaja Yakritdalludara*^[1]. Non-alcoholic fatty liver disease (NAFLD) is also otherwise termed as Hepatic steatosis and *Kaphaja yakrit dalludara* in Ayurveda, fat deposition in liver absence of excessive alcohol intake^[2]. It is a global public health due to dietary hyper nutrition subsequent obesity, type-II diabetics and associated with smoking, hypertension and dyslipidaemia.

NAFLD is an umbrella term used to described a histological spectrum ranging from simple steatosis, a concentration of hepatic triglycerides (TGs) exceeding 5% of liver weight, to non-alcoholic steatohepatitis (NASH) characterized by hepatocellular damage, lobular necroinflammation,

fibrogenesis resulting cirrhosis, and cancer^[3]. The prevalence of NAFLD is 15-40% in Western countries and 9-40% in Asia. Recent studies from the Indian subcontinent recorded a NAFLD prevalence of 9–32% in the general population⁴. Metabolic perturbations, including insulin resistance, impaired glycaemic control, and altered lipid metabolism, have been hypothesized to contribute to the molecular pathogenesis of NAFLD and NASH⁵. Various pharmacological and non-pharmacological approaches seem to be non-effective and the patients are kept on long term treatment. Hence, even the highly educated patients reach to various traditional and alternative practitioners with an expectation of positive outcome^[6]. Moreover, currently used medical treatment has been shown to be severe side effect and some have been associated with increased risk of certain type of cancer. Recent Randomised Clinical Trial demonstrated that phyto-medicine

reduces steosis severity, liver ballooning and fibrosis and can be comparable with western medical system^[7,8]. Ayurveda medication in NAFLD is in conclusive^[9,10] and limited to case studies^[11] and literature review^[12]. Although more than ten clinical trials of Ayurveda formulations are registered for NAFLD, yet more evidences required for the efficacy and safety of Ayurveda formulation in Non-alcoholic fatty liver diseases. Many patients demand for one poly herbal formulation which will be economic, no side effect and easy to take. Moreover, *Potala katurohinyadi Kwatham* is a known medicine for anorexia, vomiting, skin diseases, jaundice, viral infections and liver diseases phyto- chemical analysis is studied.^[13,14]. Therefore, this case study is unique to study the safety and efficacy of *Potala katurohinyadi Kwatham* in Non-alcoholic fatty liver diseases primarily.

Patient Information

A 34 years male patient, highly educated from a high socio-economic group of Non vegetarian diet habit came to hospital July 2018 with complain of anorexia, indigestion and distention for three months. He is a lawyer in profession and his father has been suffering from diabetic and dyslipidaemia. The patient gave the history of weight gain of 6kg within one year. No history of intravenous drug use, blood transfusion and unsafe sex practice.

The patient has taken modern appetizer, antacid and rabeprazole sodium for one month, but not satisfying with the relief. Therefore, he came for Ayurveda medication.

Clinical Findings

The case was having central obesity having 75kg weight and 163cm height (BMI-28.2). His viral hepatitis screening was negative antinuclear antibody, smooth muscle antibody, α_1 -antitrypsin, ceruloplasmin, and thyroid-stimulating hormone levels were within normal limit. His fasting blood sugar is 122mg/dl, PPBS was 162mg/dl, HbA1c was 7.1 and fasting insulin was 30mIU/L. His serum total bilirubin was 1.0mg/dl with direct was 0.3mg/dl, SGOT was 54 U/L, SGPT was 45 U/L, alkaline phosphate 138u/l, GGT (Gamma-glutamyl transferase) was 64U/L (Normal range 03-60U/L), serum urea- 26.0mg/dl (normal range 13-45mg/dl), serum creatinine 0.62 (normal range 0.6-1.2mg/dl), total protein 6.2 and serum albumin was 4.2mg/dl, Serum cholesterol was 137mg/dl, TG was 227mg/dl, HDL was 38mg/dl, Haemoglobin was 12.8gm/dl, total thrombocyte (PLT) was $148 \times 10^9/L$, TLC- 8700cells/cumm and ESR 1st hour was 06mm. He has elevated echo genicity and mild hepatomegaly in sonography report and mid line shift was 12 in liver electrography (Fibro scan).

The patient's *Dosha vidha Prikshya* (Tenfold of comprehensive bio-psycho-spiritual clinical review) as *Kapha Pitta prakruti*, *Kaphajavikruti Madyama sara*, *Madyamasamhana*, *Prabara satmya*, *Madyama Ahara Shakti* and *Vyayama Shakti*, *Madyama Vaya* and *Pramana*. The *Kosto* (Bowel Habit) was *Kruro* (constipated). The patient's *Asta vidha Prikshya* (eight fold examination) as *Kapha pitta Nadi*, normal *Mutra* and *Mala*, *Ama lipta* (coated) *Jivha*, *Kapha* predominant *Shabda*, *Sparsa* and *Drika*, slightly central obesity in *Akruti* (general appearance).

Time Line

Time line	Clinical presentation	Medication
Before Jan 2019	Asymptomatic	
Feb 2019	Heaviness, constipation	No medication
April 2019	Anorexia, indigestion, distension of abdomen	modern appetizer, antacid and rabeprazole sodium for one months
May 2019(D0)	Anorexia, indigestion, distension of abdomen and came for Ayurveda treatment	NAFLD diagnosed & <i>Potala Katurohinyadi Kwatham</i> - 30ml BID with equal quantity of water in empty stomach
Jun 2019 (D30)	No symptom	Medication continued for another two month
July 2019	No symptom and no improvement in USG and Fibroscan	Medication continued for another four month
October 2019	No symptom and improved in fibro scan	Medication stopped
Sep 2020	No symptom, Review and maintained health	Normal life without medication

Diagnostic Assessment

The diagnosis of NAFLD requires the evidence of hepatic steatosis by imaging or by histology. Ultrasound is very effective in diagnosis steatosis where more than 33% hepatocyte are steotic^[15]. The SAF score in histology is encompassment of an assessment of steatosis (S), activity (A) and fibrosis (F) which has been introduced more recently to identify NASH (Non alcoholic Steato- hepatitis) which can progress to cirrhosis and end stage liver diseases^[16]. The BARD score and NAFLD fibrosis score are simple non-invasive tests of fibrosis assessment calculated from specific software. Transient elastography (TE) provide the Liver stiffness measurement (LSM) using pulse -echo ultrasound as surrogate marker of fibrosis^[17].

Therapeutic Intervention

Patolakaturohinyadi Kwatham (PKK) is a very famous Ayurvedic medicine in decoction form. It is used in the treatment of anorexia, vomiting, skin diseases, jaundice, viral infections and liver diseases. It is used in the treatment of fever and other diseases of *Kapha* and *Pitta* origin. It is also a potent antitoxic medicine used for liver detoxification. It improves digestion and relieves anorexia. It is a potent antimicrobial medicine. The main ingredients of *Patolakaturohinyadi kwatham* are, *Patola* (*Trichosanthes dioica*), *Katurohini* (*Picroohiza kurroa*), *Chandana*- Sandal wood (*Santalum album*), *Madhusrava* (*Leptadenia reticulate*), *Guduchi* (*Tinospora cordiafolia*) and *Patha* (*Cissampelo spariera*)^[13]. The dose was 30ml *Kasaya* with equal quantity of lukewarm water twice daily in empty stomach preferable morning and evening. The treatment was given for three months initially and further extended for another three months. So total duration was done for 6 months.

Follow up and outcome

The patient was followed up in 30 days and 90 days, six month and observed for one year without medication. The patient has improved clinically and her haematological, biochemical and serological parameters gradually developed during the period of time (Table-2). The outcome was measured in terms of ultrasound and Fibro scan which showed improved in fibrosis score and not reappeared in one year of observed period.

After 30 days of treatment, his normal appetite was appeared and got relieved in abdominal discomfort, but he gained weight one kg and his blood sugar and other parameter was not changed significantly. As the patient relieved symptoms, felt good he wanted to extend his treatment, therefore the treatment was extended for further two months. There was a significant change in metabolic and liver function tests without changes in liver architecture in terms of ultrasound, fibrosis scoring and fibro scan after three months of treatment. The treatment schedule was further extended to another three months for better outcome and observed the change in fibrosis of liver. After six months of medication, there was a significant change in metabolic and liver function tests as well as liver architecture in terms of ultrasound, fibrosis scoring and fibro scan without any side effect. The BARD score changed from 4 to 2 and 0 after six month. NAFLD score <-1.455 is F0 (no fibrosis). This case has mild fibrosis to no fibrosis after three month of therapy. The patient was kept in observation for further one year without medication and advised to practice yoga, exercise and low carbohydrate and fat diet to study the recurrence of disease. The liver architecture as well as biochemical profile of liver is maintained after one year also. The prescribed medication well tolerated as we were not observed adverse clinical sign and symptoms and there is no change in Haematological, renal and Liver profile.

Table 2: Hematological, Biochemical and Serological Parameters During the Treatment and Observed Period

Lab parameters	D0	D30	D90	D180	After one year without Rx
Weight (Kg)	75	76	73	71	66
BMI	28.2	28.6	27.5	26.7	24.8
FBS (mg/dl)	122	120	84	78	82
PPBS (mg/dl)	182	178	123	118	123
HbA1C	7.1	---	6.4	6.2	5.8
Serum Insulin (Fasting) μ U/ml	30ml	----	20	12	10
Total cholesterol	139	140	120	120	122

Triglyceride	227	220	150	134	154
HDL Cholesterol	38	40	40	50	68
Haemoglobin (gm/dl)	11.7	11.6	12.4	12.6	11.8
ESR 1 st hour	06	60	50	46	50
Platelet Count (10 ⁹ /L)	148	178	192	240	238
TLC	8700	8100	8000	7800	6800
Prothrombin Time Sec	11.4	11.4	10.2	10.2	
Sr.Bilirubin (Total) mg/dl	1.0	0.8	1.79	1.2	1.0
Sr.Bilirubin (Direct) mg/dl	0.3	1.07	0.7	0.5	0.4
SGOT/ ALT(IU/L)	54	56	40	40	39
SGPT/AST(IU/L)	45	44	35	31	28
Alkaline Phosphatase (IU/L)	138	130	136	147	108
GGT(U/L)	64	63	40	04	05
Total protein	6.6	7.6	7.8	7.8	7.8
Albumin g/dl	4.2	4.2	4.6	4.6	5.2
Urea	26	18	28	30.6	27.2
Creatinine	0.62	0.60	0.65	0.76	0.5
Serum ferritin (ng/ml)	180	150	154	144	155
Ultrasound	Mild	-	No change	Normal	Normal
BARD Score	04	04	02	00	00
NAFLD fibrosis Score	-1.455	-0.91	-1.86	-3.00	-3.54
Fibroscan (Median stiffness)	12	---	9.00	6.99	6.12

TLC: Total Leukocyte Count

SGOT (AST): serum glutamic-oxaloacetic transaminase; SGPT (ALT): serum glutamic-oxaloacetic transaminase; GGT: Gamma-glutamyl transferase; ANA: anti nuclear anti body,

DISCUSSION

The presented patient is *Kapha pitta prakruti* and other Ayurvedic parameters of examination were *Kapha* predominant. Therefore, it is suggested that Ayurvedic nomenclature for Non Alcoholic Fatty Liver diseases (NAFLD) may be *Kaphaja Yakruitdalludara*. *Patolakaturohinyadi Kwatham* (PKK) is indicated for *Kapha pittaja* disorders. PKK is already studied in Alcoholic liver diseases, where the study outcome was limited to diminished the liver enzymes without observing the liver architecture by fibrosis Score, Fibro scan and ultrasound. This study proved that PKK can significantly reduced blood sugar, serum Lipids and liver enzymes within 3 months along with reduction weight and BMI, but change in liver architecture required six months in this therapy. PKK may correct the metabolic dysfunction by increase *Agni*, digest *Ama* which helped in the correction of hyperglycaemia and dyslipidaemia. PKK is safe in for six months of use in

recommended dose (30ml BID) as there was no adverse sign and symptom observed and no change in biochemical and Haematological profile of Patients. The patient was kept in observation for further one year without medication and advised to practice yoga, exercise and low carbohydrate and fat diet to study the recurrence of disease. The liver architecture as well as biochemical profile of liver is maintained after one year also. So PKK has corrected the metabolic error as NAFLD is said to metabolic associated fatty liver disease^[18].

CONCLUSION

PKK is safe and effective in this case of *Kaphaja Yakrit dalludara* (NAFLD). It can study further in large population to prove its safety and efficacy in meaningful way.

ACKNOWLEDGEMENT

The authors are very grateful to Director General and Deputy Director General, CCRAS, New Delhi for providing encouragement and guidance. The authors are thankful to the patient, who has actively cooperated for all investigation whenever required.

REFERENCES

1. Panda AK, Bhuyan GC, Rao K, Otta S, Parhi KK, Role of Meda (Liver adipocyte) in Yakrit Vikara (Liver diseases), J Ayu & Integ Med Sci 2020;2:141-147.
2. Angulo P, Non alcoholic fatty liver diseases. N. Engl. J Med 2002; 346:1221-31.
3. Byrne, C. D., Targher, G. (2015). NAFLD: a multisystem disease. J. Hepatol. 62, S47-S64. doi: 10.1016/j.jhep.2014.12.012.
4. Duseja A, Non alcoholic fatty liver diseases in India- a lot done, yet more required. Indian J Gastroenterol 2010; 29:217-225.
5. Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol. 2019; 8(2):247-267. doi:10.1016/j.jcmgh.2019.04.007
6. N. Milosevic, M. Milanovic, L. Abenavoli, N. Milic. Phytotherapy and NAFLD--from goals and challenges to clinical practice. Rev Recent Clin Trials, 9 (2014), pp. 195-203.
7. F. Hsu, L. Y. Sheen, H. J. Lin, and H. H. Chang, A review of western and traditional Chinese medical approaches to managing non-alcoholic fatty liver disease, Evidence- Based Complementary and Alternative Medicine, vol. 2016, Article ID 6491420, 12 pages, 2016.
8. Jadeja R, Derkar RV, Narmmi S. Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. Evid Based Complement Alternat Med 2014; 2014: 648308
9. Singhal P, Nesari T, Gupta GS. Efficacy of herbomineral compounds and pathya (Ayurvedic dietary regime and physical exercise) in the management of Yakrt Roga (Non-alcoholic fatty liver disease) Anc Sci Life. 2015;34:216-22
10. M. Suriyavathana Vedanarayanan and N. Krishnan, "Ayurvedic formulation of Liv-Pro-08 reduces nonalcoholic fatty liver disease in rats fed with high-fat diet, Journal of Acupuncture and Meridian Studies, vol. 4, no. 4, pp. 236-241, 2011.
11. Panda A K, Das D, Dixit A, Giri R K, Hazra J, "The effect of Arogya vardhini vati and Phalatrikadi kwatha in NAFLD: case study, Int. J Adv in case report, 2016; 2016: 3, 59-62.
12. Remya E & Mandip G, Non-alcoholic fatty liver disease (NAFLD): An Ayurvedic Pragmatic Approach with Its Management, International Journal of Ayurvedic and Herbal Medicine 7:6 (2017) 2948-2955.
13. Mudiganti R K Rao entitled, Phytochemical and GCMC Analysis of Ayurveda Formulation Phatala katurohinyadi Kwatham. Int. J. Pharm. Sci. Rev. Res., 34(2), September - October 2015. 02: 6-12.
14. Pawar S, Kadam R & Jawale S (2015) .An Randomised open study of Patalokaturhinyadi Kasayam in Alcoholic liver disease. International Journal of Ayurveda & Pharma Research, 2015; 3(7):15-20
15. Burt AD, Lackner C, Tiniakos DG. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin Liver Dis. 2015 Aug; 35(3):207-20. doi: 10.1055/s-0035-1562942. Epub 2015 Sep 17. PMID: 26378639.
16. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in Non-alcoholic fatty liver disease. Gastroenterology 2002;123:745-50
11. Sasso M, Tengher-Barna Zioli M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan (R): validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-53.
12. Mohammed Eslam, Arun J Sanyal, Jacob George. MAFLD- A consensus driven proposal for metabolic associated fatty liver disease. Gastroenterology 2020; 158(7):1999-2014.

Cite this article as:

Ashok Kumar Panda, Jayram Hazra. Potala Katurohinyadi Kwatha In Kaphaja Yakrit Dalludara (Non-Alcoholic Fatty Liver Disease): A Case Study. International Journal of Ayurveda and Pharma Research. 2020;8(11):62-66.

Source of support: Nil, Conflict of interest: None Declared

*Address for correspondence

Dr Ashok Kumar Panda

Research Officer,

Central Ayurveda Research

Institute for Hepato biliary

Disorders, Bharatpur,

Bhubaneswar.

Email : akpanda_06@yahoo.co.in

Disclaimer: IJAPR is solely owned by Mahadev Publications - dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJAPR cannot accept any responsibility or liability for the articles content which are published. The views expressed in articles by our contributing authors are not necessarily those of IJAPR editor or editorial board members.